Member login | Not a member? Sign up
Cambridge Cognition develops cognition tests, known as CANTAB, that can be used to diagnose early-stage neurological diseases. The rights to the tests were acquired from former Aim company CeNeS Pharmaceuticals. Cambridge Cognition raised £5m at 70p a share prior to floating on 18 April 2013 at a valuation of £11.8m.
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds